Market Access Impact (EU5) [CLL]

Thursday, July 6, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 5, 2017 /PRNewswire/ -- How are market barriers moving the goalposts for CLL drugs in Europe?Just

how significantly are market barriers skewing prescribing behaviour for CLL drugs in Europe? One drug is clearly popular and others are playing 'catch-up' on the market share stakes – but what difference would it make
if the landscape shifted and non-clinical constraints such as cost, availability, administrative restrictions, institutional guidelines, and patient preferences were removed or changed?Market Access Impact: CLL (EU5) examines the dynamics of the CLL drug market in Europe. It specifically looks at how various market access barriers are impacting the 5 most popular CLL drugs from Gilead, Janssen, Roche and Novartis/Genmab.........Top TakeawaysTotal recall: One anti-CD20 brand has proved popular with oncologists, and 100% of those surveyed said they either use or would consider it. How well do other brands do in the awareness stakes?Spoilt for choice: Physicians have a choice of effective CLL treatment options, but 1 in 5 prescribing decisions are affected by market barriers. Find out which ones apply to which drugs.Look for the positives: Barriers cause two thirds of oncologists to prescribe other than their first choice – and two brands are benefitting. Why are market barriers an advantage for some?Not what it seems: One brand gains almost 4% share due to market barriers which looks great at first glance – but there's bigger loss overall. Find out the detail behind the top line.Different stories: All 5 drugs in the survey show different impact patterns due to market barriers. What should be the priority for individual market access teams?Insight into 5 Leading CLL DrugsArzerra (ofatumumab; Novartis/Genmab)Gazyvaro (obinutuzumab; Roche)Imbruvica (ibrutinib; Janssen)MabThera (rituximab; Roche)Zydelig (idelalisib; Gilead)Lifting the lid on Market Access issuesMarket Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You'll learn:How barriers affect market access:Which CLL brands are physicians prescribing the most?How are prescribing decisions being affected by market barriers?Are some barriers having more impact than others?How barriers affect your brand:How many doctors prescribe your brand? How many don't, but would consider it?Why don't doctors prescribe your brand? What do they choose instead?Which competing brands does your brand take market share from?A Report Based on Expert KnowledgeWe surveyed 150 oncologists and haematologists in the EU5 (France, Italy, Germany, Spain, UK).All respondents have:Been practising for 2+ yearsPrescribed at least one of the listed productsSeen at least 5 chronic lymphocytic leukaemia patients in total in the last monthWe conducted the survey between 2nd and 8th May 2017.Download the full report: https://www.reportbuyer.com/product/4967740/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected]  Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/market-access-impact-eu5-cll-300483571.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store